Claimed effect · Mazdutide

Does Mazdutide help with liver fat?

B
Grade B — probable, not settledPhase 3 sub-analyses · effect size: large
Short answerProbable, not settled. Human data exist (Phase 3 sub-analyses) and mostly agree, showing a large effect — but too few, too small, or not yet peer-reviewed for a firm answer. Among participants with baseline liver fat above 10%: −66% (4 mg) and −80% (6 mg) versus −5% in GLORY-1; −72% versus +5% in GLORY-2.

What the studies show

Among participants with baseline liver fat above 10%: −66% (4 mg) and −80% (6 mg) versus −5% in GLORY-1; −72% versus +5% in GLORY-2.

Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.

  1. 1
    Ji L, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1).N Engl J Med, 2025; DOI 10.1056/NEJMoa2411528610 adults, 48 weeks.
  2. 2
    Innovent. Mazdutide 9 mg achieves up to 20.1% weight loss in Chinese adults with obesity (GLORY-2 topline).Press release, 19 Nov 2025462 adults, 60 weeks; topline, not yet peer-reviewed.

In context

Mazdutide is a once-weekly GLP-1/glucagon dual agonist developed by Innovent with Lilly. In the 610-person GLORY-1 trial, published in the New England Journal of Medicine in May 2025, it produced 14.8% weight loss at 48 weeks on 6 mg against 0.5% on placebo; a 9 mg dose reached 18.6% at 60 weeks in GLORY-2. China's regulator approved it for chronic weight management on 27 June 2025 and later for type 2 diabetes. It is not approved in the US, EU or UK.

Mazdutide is approved in china only. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Mazdutide proven to help with liver fat?
Not yet settled. Phase 3 sub-analyses — LYO grades it B, meaning probable but liable to change as trials read out.
What studies are behind the grade?
Among participants with baseline liver fat above 10%: −66% (4 mg) and −80% (6 mg) versus −5% in GLORY-1; −72% versus +5% in GLORY-2.
Is Mazdutide approved for this?
Mazdutide is an approved medicine (Approved in China only); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Mazdutide

Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →